Greenland Mines Ltd

Greenland Mines Ltd, founded in 2004 and headquartered in Omaha, Nebraska, operates as a diversified company with interests in both natural resources and cell and gene therapy. The company's core mission involves unlocking the potential of the Skaergaard Intrusion for critical minerals and developing innovative therapies for neurodegenerative diseases.

In its natural resources division, Greenland Mines Ltd is focused on the exploration and development of the Skaergaard Project in Southeast Greenland. This project is recognized as one of the world's largest undeveloped deposits of palladium, gold, and platinum, with an estimated in-situ resource value of approximately $68 billion at February 2026 metal prices. The company also aims to expand its raw critical metals portfolio to include vanadium and gallium. Concurrently, its cell and gene therapy division is dedicated to developing treatments for neurodegenerative disorders such as Alzheimer's, amyotrophic lateral sclerosis (ALS), and Parkinson's, with a specific focus on its KLTO-202 program for ALS.

Greenland Mines Ltd, which rebranded from Klotho Neurosciences, Inc. in March 2026, is publicly traded on NASDAQ under the ticker GRML. Dr. Joseph Sinkule serves as the Founder, CEO, and Chairman of the Board, while Bo Møller Stensgaard is President, overseeing the natural resources segment. Recent developments include securing an additional 180-day period for Nasdaq bid price compliance, engaging WSP Denmark for an Environmental Impact Assessment (EIA) at Skaergaard, and signing a Letter of Intent for an Icelandic industrial processing site, underscoring its strategic positioning in the critical minerals supply chain.